Distinct prognostic value of circulating anti-telomerase CD4⁺ Th1 immunity and exhausted PD-1⁺/TIM-3⁺ T cells in lung cancer.

ABSTRACT:

Background

Despite the critical roles of Th1-polarised CD4⁺ T cells in cancer immunosurveillance, the translation of their potential to clinical use remains challenging. Here, we investigate the clinical relevance of circulating antitumor Th1 immunity in non-small cell lung cancer (NSCLC).

Methods

The circulating antitumor Th1 response was assessed by the ELISpot assay in 170 NSCLC patients using a mixture of HLA class II-restricted peptides from telomerase (TERT). Phenotyping of blood immune cells was performed by flow cytometry.

Results

TERT-reactive CD4 T-cell response was detected in 35% of NSCLC patients before any treatment. Functional analysis showed that these cells were effector memory and Th1 polarised capable to produce effector cytokines, such as IFN-γ, TNF-α and IL-2. The presence of anti-TERT Th1 response was inversely correlated with the level of exhausted PD-1⁺/TIM-3⁺CD4 T cells. The level of these two immune parameters differentially affected the survival, so that increased level of anti-TERT Th1 response and low rate of exhausted PD-1⁺TIM-3⁺CD4⁺ T cells were associated with a better prognosis.

Conclusions

Systemic anti-TERT Th1 response plays a strong antitumor protective role in NSCLC. This study underlines the potential interest of monitoring circulating antitumor Th1 response for patients' stratification and therapy decision.

SUBMITTER: Laheurte C 

PROVIDER: S-EPMC6738094 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature